Compare AbbVie Inc (ABBV) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Riot Platforms Inc — how do they compare? AbbVie Inc trades at $247.46 (market cap $441.94B), while Riot Platforms Inc trades at $20.69 (market cap $7.59B). The key difference: AbbVie Inc is far larger — about 58.2× Riot Platforms Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| ABBV | RIOT | |
|---|---|---|
Market Cap | $441.94B | $7.59B |
Sector | Health | Technology |
52-Week High | $263.58 | $28.67 |
52-Week Low | $197.38 | $11.33 |
Enterprise Value | $506.19B | $8.00B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
RIOT Platforms trades at $20.90, up 7.73% in the last 24 hours, following the announcement of a landmark $9.1 billion, 20-year AI data center deal with Anthropic. Despite this positive news, the technical outlook remains bearish, and the company continues to report significant net losses, with a net income margin of -196.28% for 2026. Analyst sentiment is overwhelmingly positive, with a consensus price target of $33.40 representing substantial upside potential.
The stock presents a high-risk, high-reward opportunity. The transformative AI deal offers a clear long-term growth catalyst, but investors must weigh this against persistent unprofitability and negative cash flows. The key risk is the company's ability to execute its strategic pivot to AI infrastructure while managing its financial losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
